ClinicaliQ Trial Snapshot
- A Study of How the Medicine Called “Etrasimod” Works in Children With the Gut Disease Called Ulcerative Colitis — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT07470879.
- Drug being tested: Etrasimod, a selective sphingosine-1-phosphate receptor modulator, is being evaluated for safety, efficacy, and pharmacokinetics in children aged 2 to <12 years with moderately to severely active ulcerative colitis.
- Patient eligibility overview: The trial recruits paediatric patients (≥2 years to <12 years old) diagnosed with moderately to severely active ulcerative colitis, representing an understudied population in inflammatory bowel disease treatment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to < 12 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).
Eligibility Snapshot
- : Have a diagnosis of ulcerative colitis (UC) that is moderately to severely active Participants are permitted to be receiving a therapeutic dose of select UC therapies
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.